United Therapeutics (NASDAQ:UTHR) Stock: Insider Martine Rothblatt Sells 9,500 Shares

Key Points

  • CEO Martine Rothblatt sold 9,500 shares for about $5.58 million, reducing her ownership by 2.84%; she retained 324,443 shares after the transaction.
  • United Therapeutics’ latest quarter showed mixed results: EPS of $5.71 fell short of estimates, while revenue of $832.5 million exceeded forecasts and grew 4.1% year over year.
  • The board authorized a $2 billion share buyback, allowing repurchases of up to 8.3% of shares. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $676.40.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $587.74, for a total value of $5,583,530.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $190,688,128.82. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Down 0.6%

NASDAQ:UTHR opened at $584.10 on Wednesday. The firm has a market capitalization of $24.88 billion, a price-to-earnings ratio of 22.04, a price-to-earnings-growth ratio of 3.91 and a beta of 0.49. United Therapeutics Corporation has a twelve month low of $455.63 and a twelve month high of $614.23. The stock's 50 day moving average price is $546.33 and its two-hundred day moving average price is $537.56.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.01 by ($0.30). The company had revenue of $832.50 million for the quarter, compared to the consensus estimate of $781.14 million. United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The company's revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $7.16 EPS. As a group, analysts anticipate that United Therapeutics Corporation will post 25.08 earnings per share for the current year.




United Therapeutics declared that its Board of Directors has authorized a share buyback program on Thursday, October 22nd that permits the company to buy back $2 billion in shares. This buyback authorization permits the biotechnology company to reacquire up to 8.3% of its shares through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in UTHR. Toth Financial Advisory Corp lifted its holdings in United Therapeutics by 2,400.0% during the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 48 shares during the last quarter. Fiduciary Financial Advisors bought a new position in United Therapeutics during the second quarter worth $30,000. Gen Wealth Partners Inc bought a new position in United Therapeutics during the third quarter worth $34,000. Caitlin John LLC acquired a new position in shares of United Therapeutics in the second quarter valued at $37,000. Finally, PFS Partners LLC acquired a new position in shares of United Therapeutics in the third quarter valued at $45,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on UTHR. Morgan Stanley increased their price target on shares of United Therapeutics from $515.00 to $566.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 7th. Cantor Fitzgerald reissued an "overweight" rating and issued a $850.00 price objective on shares of United Therapeutics in a research report on Monday, October 26th. Raymond James Financial set a $720.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 4th. Weiss Ratings cut shares of United Therapeutics from a "buy (b-)" rating to a "hold (c+)" rating in a report on Monday, November 9th. Finally, Wells Fargo & Company upped their target price on shares of United Therapeutics from $700.00 to $703.00 and gave the company an "overweight" rating in a report on Thursday, November 5th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $676.40.

Get Our Latest Research Report on UTHR

About United Therapeutics

(Get Free Report)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.

Featured Articles

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at United Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for United Therapeutics and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles